Genetic test-guided treatment for newly diagnosed peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have peripheral T-cell lymphoma confirmed by biopsy (tissue sample).
- You can provide lymphoma tumor tissue (stored or newly collected) that’s enough for genetic testing.
- You have at least one measurable spot that doctors can track on a PET-CT or CT scan.
- Your general health is good enough for treatment (ECOG 0–2) and you’re expected to live at least 3 months.
- You can sign informed consent, and your blood and organ test results are within required limits (unless abnormal due to lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.